Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04495010
Title Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)
Acronym CheckMate 7UA
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: senior | adult | child
Covered Countries USA | SWE | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS


No variant requirements are available.